Bill would curb unethical drug maker payments to physicians

Share this content:

Senate Finance Committee ranking member Charles Grassley (R-IA) plans to introduce legislation that would crack down on dubious payments from drug companies to physicians.

Under the legislation, drug makers would have to inform the public through a federal registry about payments made to any physician who bills the Medicare and Medicaid programs. Several states, including Minnesota, Vermont and Maine, have state-level registries.

In a speech to the Senate last week, Grassley cited the case of a child psychiatrist who made $180,000 in just over two years from AstraZeneca for work on the antipsychotic drug Seroquel, which now is widely used in children.
close

Next Article in News